Truncated IGF-1 analog – Kodiac biolabs

Plain-language summaryIntrigue 58 / 100

IGF-1 DES is a truncated form of IGF-1 missing the first three amino acids. The truncation reduces binding to IGF-binding proteins, producing a more potent local muscle effect. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

45/100

IGFBP-resistant IGF-1 fragment with real local potency advantage but thin human data and dated novelty

IGF-1 DES is the truncated cousin of native IGF-1: lose the first three residues (Gly-Pro-Glu) and you drop IGFBP binding substantially, which means the free fraction at target tissue goes up and local potency climbs roughly 10-fold over native IGF-1 in head-to-head in vitro models. That’s a real pharmacological distinction, and it’s why this form shows up specifically in muscle, bone, and neural tissue studies where local receptor activation is the question you’re actually asking.

What we like: the IGFBP angle is genuinely useful as a research probe. IGF binding proteins are a confounding layer in nearly every IGF-1 study, and DES lets you bypass that layer directly. If you’re interrogating IGF-1R signaling in tissue culture or local injection models, DES produces a cleaner readout than native IGF-1 without the IGFBP sink eating your signal. The receptor binding characteristics are documented across multiple lab groups, the functional potency difference is reproducible, and the mechanism is well-defined enough that you know what question you’re answering when you use it.

The problem is that this compound has been around since the late 1980s. The core biochemistry, characterized by Ballard and colleagues and expanded substantially by Sara and Hall in the early 1990s, is thoroughly mapped. The truncation strategy is elegant, but its a 35-year-old elegance. Compared to a mitochondrial-derived peptide or a novel triple incretin, DES sits firmly in the established-but-not-exciting column. Novelty here is historical, not current.

Versus IGF-1 LR3, the comparison is real and worth making: LR3 extends half-life to hours via the Arg3 modification, which suits systemic and sustained-release models. DES gives you a 20-30 minute half-life with higher peak local effect, which fits local-injection tissue models better. These are genuinely different tools for genuinely different questions, not just dose variants. That differentiation earns DES a niche. It doesn’t, however, make it dominant in the broader IGF research space where LR3 has the deeper translational literature.

What we dont love: human-specific data on the DES form is sparse. Most clinical IGF-1 work uses native IGF-1 or mecasermin. The case that DES specifically outperforms in a human research context is largely extrapolated from preclinical, and the short half-life doesn’t meaningfully reduce systemic exposure under repeated-dosing protocols. The same proliferative risk considerations that shadow native IGF-1 apply here in full.

Honestly, DES earns its place in an IGF toolkit as a mechanistic probe. It’s not a headline compound in 2026. Real pharmacological distinction, solid bench utility in local tissue models, but the novelty window on this one closed a generation ago.

Novelty: 38
Mechanism promise: 52
In-category differentiation: 48
Evidence quality: 42
Translational signal: 38
Research bench value: 58

Rationale IGF-1 DES is a well-characterized truncation with a genuine pharmacological distinction (IGFBP bypass, ~10x local potency) that earns real bench utility, but the core biochemistry was mapped in the late 1980s and human-specific DES evidence remains sparse relative to LR3 or native IGF-1. Scores reflect a solid but non-exciting tool compound with modest translational signal.

Truncated IGF-1 analog

A truncated form of IGF-1 missing the first three residues, with reduced IGFBP binding and increased local potency.

Abstract

IGF-1 DES (DES(1-3) IGF-1) is a truncated analog of human IGF-1 missing the first three N-terminal residues (Gly-Pro-Glu). The truncation reduces binding to IGF binding proteins (IGFBPs) and increases the free fraction of the peptide at target tissues, producing approximately 10-fold higher local potency than native IGF-1 at equivalent doses. The compound is sold as a research chemical. Plasma half-life is shorter than IGF-1 LR3 (approximately 20 to 30 minutes for IGF-1 DES vs hours for LR3) due to the absence of the Arg3 modification, but the increased local activity provides higher peak effects per dose. Investigational doses range widely; safety considerations parallel IGF-1 LR3 (chronic IGF-1 elevation effects on cancer risk and acromegalic features).

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-088Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: Truncated IGF-1 analog

IGF-1 DES

Abstract

Read the full monograph